<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Neonatal target oxygen levels for preterm infants
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Neonatal target oxygen levels for preterm infants
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Neonatal target oxygen levels for preterm infants
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Martin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2652938645">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxygen supplementation is an important component of neonatal intensive care for the preterm infant. Ideally, oxygen administration provides adequate oxygenation for the metabolic needs of the neonate while avoiding the consequences of both hypoxemia and hyperoxia.
        </p>
        <p>
         Neonatal target oxygen levels for the preterm infant is discussed here. Oxygen delivery and monitoring and mechanical ventilation in the newborn are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2791765501">
         <span class="h1">
          SpO2 AND PaO2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Normal values for hemoglobin oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) reach or exceed 80 percent within 10 minutes of birth in term and healthy preterm infants without supplemented oxygen [
         <a href="#rid1">
          1
         </a>
         ]. In general, arterial partial pressure of oxygen (PaO
         <sub>
          2
         </sub>
         ) values of 50 to 80 mmHg are adequate to meet metabolic demands of the neonate in part due to the greater proportion of fetal hemoglobin (HbF).
        </p>
        <p class="headingAnchor" id="H1677921800">
         <span class="h2">
          Use of SpO2 for targeting oxygen levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         For neonates receiving supplemental oxygen therapy, target oxygen levels are based on peripheral oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) measured noninvasively with continuous pulse oximetry. Arterial blood gas (ABG) samples, which measure arterial oxygen tension (PaO
         <sub>
          2
         </sub>
         ), may be obtained periodically to correlate with pulse oximetry measurements and further assess the neonate's ventilatory status (eg, pH and carbon dioxide level).
        </p>
        <p>
         However, ABG measurements require blood sampling, either through indwelling catheters or percutaneous puncture of a palpable artery. ABG measurements may change during percutaneous punctures as the infant responds to the procedure. Clinicians should be mindful of this when interpreting the results. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Pulse oximetry'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Arterial blood gas measurement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2400781226">
         <span class="h2">
          Correlation between PaO2 and SpO2
         </span>
         <span class="headingEndMark">
          —
         </span>
         In neonates, SpO
         <sub>
          2
         </sub>
         levels between 85 and 95 percent generally correlate to PaO
         <sub>
          2
         </sub>
         levels between 45 and 65 mmHg  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid2">
          2,3
         </a>
         ]. However, pulse oximetry measurements are less reliable for detecting hyperoxemia or severe hypoxemia. For example, at saturations &gt;96 percent, PaO
         <sub>
          2
         </sub>
         values can continue to increase with little or no further corresponding change in SpO
         <sub>
          2
         </sub>
         .
        </p>
        <p>
         Neonates have increased levels of HbF which has a high affinity for oxygen. This is an important factor to consider when setting SpO
         <sub>
          2
         </sub>
         targets. HbF shifts the oxygen dissociation curve to the left, which may result in high oxygen saturation (eg, 85 percent) at PaO
         <sub>
          2
         </sub>
         levels below 45 mmHg  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 1
         </a>
         ). The proportion of HbF increases with decreasing gestational age (GA) so that the concentration of HbF in an infant born at 28 weeks gestation is approximately 90 percent.
        </p>
        <p>
         Because of these complex interactions, preterm infants at high risk for hyperoxemia or severe hypoxemia, as well as those with rapidly changing cardiopulmonary status, require periodic ABG determination. (See
         <a class="medical medical_review" href="/z/d/html/4962.html" rel="external">
          "Anemia of prematurity (AOP)", section on 'Physiologic consequences'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3158632412">
         <span class="h1">
          OXYGEN TARGET LEVELS
         </span>
        </p>
        <p class="headingAnchor" id="H1720774780">
         <span class="h2">
          Goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of supplemental oxygen therapy in preterm infants are to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meet the metabolic needs of the infant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoid hyperoxia and high concentrations of oxygen, which contribute to bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP). (See
         <a class="medical medical_review" href="/z/d/html/6263.html" rel="external">
          "Retinopathy of prematurity (ROP): Risk factors, classification, and screening", section on 'Risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Oxygen toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoid hypoxemia, which is associated with increased risk of mortality and neurodevelopmental impairment. (See
         <a class="local">
          'Supporting evidence'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1713383679">
         <span class="h2">
          Targets during delivery room resuscitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         SpO
         <sub>
          2
         </sub>
         targets for neonates undergoing resuscitation in the delivery room are summarized in the table  (
         <a class="graphic graphic_table graphicRef138322" href="/z/d/graphic/138322.html" rel="external">
          table 1
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">
          "Neonatal resuscitation in the delivery room", section on 'Pulse oximetry'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3056108901">
         <span class="h2">
          Targets for neonates requiring ongoing respiratory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         For preterm neonates requiring ongoing oxygen therapy in the neonatal intensive care unit (NICU), our suggested approach to setting target ranges for SpO
         <sub>
          2
         </sub>
         according to gestational age (GA) is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extremely preterm (EPT) infants
         </strong>
         <strong>
          (GA &lt;28 weeks)
         </strong>
         – We recommend a SpO
         <sub>
          2
         </sub>
         target range of 90 to 95 percent for EPT infants during the first few weeks after birth [
         <a href="#rid4">
          4,5
         </a>
         ]. EPT infants are most vulnerable to the effects of both high and low oxygenation levels. This target range minimizes both the low and high extreme oxygenation levels that are associated with adverse outcomes, and it is supported by the clinical trial data described below. (See
         <a class="local">
          'Supporting evidence'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the infant still requires supplemental oxygen when the corrected postmenstrual age (PMA) is &gt;32 weeks, the target the SpO
         <sub>
          2
         </sub>
         target can be increased to &gt;95 percent. There is a paucity of data regarding oxygen target ranges as the EPT infant advances in age. The rationale for using a higher target at this age is that by two to three weeks postnatal age, the risk of intermittent hypoxia increases, which may aggravate ROP by enhancing retinal proliferation [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6263.html" rel="external">
          "Retinopathy of prematurity (ROP): Risk factors, classification, and screening", section on 'Vascularization in retinopathy of prematurity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Very preterm (VPT) and moderate preterm infants
         </strong>
         <strong>
          (GA 28 to &lt;34 weeks)
         </strong>
         – We also suggest a SpO
         <sub>
          2
         </sub>
         target range of 90 to 95 percent for preterm infants &lt;34 weeks GA. Although data are lacking in more mature infants, indirect data from trials in EPT infants support this practice and this target range appears to be safe for preterm infants ≥28 weeks GA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late preterm infants (GA 34 to &lt;37 weeks)
         </strong>
         – In late preterm infants, the risk of ROP is very low, and the upper limit of the target range can be increased to 97 percent [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conditions that require individualized SpO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          targets
         </strong>
         – For infants with the following conditions, the SpO
         <sub>
          2
         </sub>
         target should be individualized based upon the clinical status of the neonate:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         BPD (see
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Supplemental oxygen'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cyanotic congenital heart disease (see
         <a class="medical medical_review" href="/z/d/html/5785.html" rel="external">
          "Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'General supportive care'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent pulmonary hypertension of the newborn (see
         <a class="medical medical_review" href="/z/d/html/135094.html" rel="external">
          "Persistent pulmonary hypertension of the newborn (PPHN): Management and outcome", section on 'Gas exchange targets'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3392517234">
         <span class="h2">
          Supporting evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of using an intermediate SpO
         <sub>
          2
         </sub>
         target range (ie, 90 to 95 percent) relative to higher (&gt;95 percent) or lower (85 to 89 percent) ranges has been demonstrated in clinical trials and meta-analyses [
         <a href="#rid8">
          8-15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermediate versus higher SpO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          target
         </strong>
         – The STOP-ROP (Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity) trial established the efficacy of an intermediate SpO
         <sub>
          2
         </sub>
         target relative to a higher target. The trial enrolled 649 infants who were randomly assigned to a SpO
         <sub>
          2
         </sub>
         target range of 89 to 94 percent or 96 to 99 percent [
         <a href="#rid8">
          8
         </a>
         ]. Infants in the lower target group had lower rates of BPD and shorter duration of hospitalization compared with those in the higher target group. This trial is described in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/111238.html" rel="external">
          "Retinopathy of prematurity (ROP): Treatment and prognosis", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermediate versus lower SpO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          t
         </strong>
         <strong>
          <sub>
           a
          </sub>
         </strong>
         <strong>
          rget –
         </strong>
         Several clinical trials have evaluated the impact of targeting an intermediate SpO
         <sub>
          2
         </sub>
         (91 to 95) versus a lower target (85 to 89) [
         <a href="#rid9">
          9-16
         </a>
         ]. In a meta-analysis of five trials (&gt;4500 neonates), mortality was lower among neonates assigned to the intermediate SpO
         <sub>
          2
         </sub>
         target compared with the lower target (17 versus 20 percent; relative risk [RR] 0.86, 95% CI 0.76-0.97) [
         <a href="#rid12">
          12
         </a>
         ]. Rates of major disability at 18 to 24 months corrected age were similar in both groups (38 versus 39 percent). Fewer patients in the intermediate target group developed necrotizing enterocolitis (9 versus 11 percent; RR 0.81, 95% CI 0.68-0.95). However, rates of ROP were higher in the intermediate target group (15 versus 11 percent; RR 1.39, 95% CI 1.18-1.64). Similar findings were noted in three other meta-analyses of the same five trials [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There have been several follow-up publications of these trials that include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A post-hoc analysis of one of the trials (Canadian Oxygen Trial [COT]) evaluated the impact of profound desaturation episodes on mortality and long-term neurodevelopment [
         <a href="#rid17">
          17
         </a>
         ]. The analysis found that prolonged hypoxemic episodes (defined as SpO
         <sub>
          2
         </sub>
         &lt;80 percent for ≥1 minute) during the first two to three months after birth were associated with late mortality or neurodevelopmental impairment at 18 months corrected age. Of note, the association between exposure to prolonged hypoxemic episodes and the primary outcome of death and neurodevelopmental impairment was stronger for infants randomly assigned to the high oxygen saturation target range (91 to 95 percent) than for those assigned to the low target range (85 to 89 percent). The authors speculated that these episodes of prolonged hypoxemia in infants assigned to the high oxygen target levels represented greater drops of saturations from baseline values resulting in more severe disturbance of oxygen homeostasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A post-hoc analysis of another trial (Surfactant, Positive Pressure, and Oxygenation Randomized Trial [SUPPORT]) evaluated the impact of intermediate versus lower oxygen targets according to whether the infant was small for gestational age (SGA) or appropriate for gestational age (AGA). Overall, hospital mortality was higher among SGA infants (38 versus 16 percent) [
         <a href="#rid18">
          18
         </a>
         ]. For the subgroup of SGA infants, mortality was lower for the infants assigned to the intermediate SpO
         <sub>
          2
         </sub>
         target compared with the lower target (26 versus 56 percent, respectively), whereas for the subgroup of AGA infants, mortality was similar in both arms (18 versus 15 percent). This subgroup effect was also seen in other trials, although the difference was less dramatic in a pooled analysis of all five trials [
         <a href="#rid15">
          15
         </a>
         ]. Mortality was highest among SGA infants with a high number of hypoxic events lasting &gt;20 seconds in the first three days after birth [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a follow-up study of SUPPORT, growth measurements during the hospitalization (birth to 36 weeks postmenstrual age [PMA]) and at 18 to 22 months corrected age were similar in both the intermediate and lower target oxygen groups [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H170466838">
         <span class="h2">
          Challenges adhering to oxygen targets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintaining infants within the targeted range remains challenging, as illustrated by the following [
         <a href="#rid21">
          21-24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective Australian study of 45 preterm infants (mean GA 30 weeks) receiving continuous positive airway pressure (CPAP) and supplemental oxygen, continuous pulse oximetry monitoring over a 24-hour period demonstrated that infants were in the target SpO
         <sub>
          2
         </sub>
         range for only 31 percent of the total recording time [
         <a href="#rid23">
          23
         </a>
         ]. There were 48 episodes of severe hyperoxia (defined as SpO
         <sub>
          2
         </sub>
         ≥98 percent) and 9 episodes of severe hypoxemia (defined as SpO
         <sub>
          2
         </sub>
         &lt;80 percent). On average, infants required 25 adjustments in the fraction of inspired oxygen (FiO
         <sub>
          2
         </sub>
         ) during the 24-hour study period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another multicenter cohort study involving 84 infants manages at 12 NICUs, centers maintained infants within their intended range 16 to 64 percent of the time but they were above range 20 to 73 percent of the time [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These findings highlight the difficulty of keeping infants in the desired target range. Guidelines and institutional protocols for oxygen therapy in preterm neonates should acknowledge these challenges and should aim for a safe SpO
         <sub>
          2
         </sub>
         range that can reliably be achieved in the real world practice setting.
        </p>
        <p>
         Novel technology using automated systems with closed loop feedback may enhance consistency of adhering to oxygen saturation targets compared with the current method of manual control of FiO
         <sub>
          2
         </sub>
         [
         <a href="#rid25">
          25-30
         </a>
         ]. Although encouraging, data are only from short-term observational studies and do not provide information on the impact of these new systems on patient outcomes [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1677539540">
         <span class="h1">
          CEREBRAL OXIMETRY
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not use cerebral oximetry monitors routinely in neonatal practice since the available evidence suggests they do not improve outcomes [
         <a href="#rid32">
          32-34
         </a>
         ]. However, cerebral oximetry may be used in select circumstances such as neonates undergoing major surgery.
        </p>
        <p>
         Monitoring cerebral oxygenation has been proposed as a means of identifying neonates with inadequate oxygen delivery, which can occur as a consequence of hypoxemia from respiratory disease, poor perfusion from cardiovascular compromise, excessive metabolic demand (eg, fever, seizure), or a combination of these factors. Cerebral oximetry monitors use near-infrared spectroscopy (NIRS) to provide noninvasive continuous monitoring of cerebral oxygenation. A persistently low reading is associated with increased risk of mortality and other adverse outcomes (necrotizing enterocolitis, neurologic injury, and neurodevelopmental impairment later in childhood) [
         <a href="#rid35">
          35-39
         </a>
         ]. Thus, it has been proposed that cerebral oximetry monitoring may be useful in neonatal practice since low values may signal the need for intervention to improve oxygen delivery (eg, optimizing respiratory support, improving perfusion with a fluid bolus or vasopressor, increasing oxygen carrying capacity with a red blood cell transfusion, or reducing oxygen demand with sedation).
        </p>
        <p>
         Cerebral oximetry has been studied in various clinical settings, including neonates undergoing cardiac surgery [
         <a href="#rid40">
          40,41
         </a>
         ], neonates with septic shock [
         <a href="#rid42">
          42
         </a>
         ], neonates at risk for intraventricular hemorrhage (ie, extremely preterm [EPT] neonates) [
         <a href="#rid32">
          32
         </a>
         ], and neonates with established cerebral injury including hypoxic-ischemic encephalopathy [
         <a href="#rid43">
          43-45
         </a>
         ]. Based on the available clinical trial data, routine use of cerebral oximetry in preterm neonates does not appear to improve outcomes [
         <a href="#rid32">
          32-34
         </a>
         ]. In the largest trial, which involved 1579 EPT infants randomly assigned to treatment guided by cerebral oximetry or standard care without cerebral oximetry during the first 72 hours after birth, mortality was similar in both groups (21 versus 20 percent, respectively) as was the risk of severe brain injury (24 percent in both groups) [
         <a href="#rid32">
          32
         </a>
         ]. Further studies are needed to identify whether there are clinical settings wherein this tool may improve neonatal outcomes.
        </p>
        <p>
         The use of NIRS monitoring in neonates with shock or intraventricular hemorrhage is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/126605.html" rel="external">
          "Neonatal shock: Management", section on 'Monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5000.html" rel="external">
          "Germinal matrix and intraventricular hemorrhage (GMH-IVH) in the newborn: Management and outcome", section on 'Monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H517673887">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring oxygenation using SpO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         – For neonates receiving supplemental oxygen, target levels are based on peripheral oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) measured noninvasively with pulse oximetry. Arterial blood gas (ABG) samples, which measure arterial oxygen tension (PaO
         <sub>
          2
         </sub>
         ), may be obtained periodically to correlate with pulse oximetry measurements and further assess the neonate's ventilatory status (eg, pH and carbon dioxide level). (See
         <a class="local">
          'Use of SpO2 for targeting oxygen levels'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Correlation between PaO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          and SpO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         – In neonates, SpO
         <sub>
          2
         </sub>
         levels between 85 and 95 percent generally correlate to PaO
         <sub>
          2
         </sub>
         levels between 45 and 65 mmHg  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 1
         </a>
         ). However, pulse oximetry measurements are less reliable for detecting hyperoxemia or severe hypoxemia. Neonates have an increased concentration of fetal hemoglobin (HbF), which has a high affinity for oxygen (ie, it shifts the oxygen dissociation curve to the left). This must be considered when interpreting SpO
         <sub>
          2
         </sub>
         levels in neonates; HbF levels increase with decreasing gestational age (GA). (See
         <a class="local">
          'Correlation between PaO2 and SpO2'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SpO
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          target levels
         </strong>
         – An optimal target SpO
         <sub>
          2
         </sub>
         range provides adequate oxygenation that meets the metabolic needs of the neonate while avoiding high concentrations of oxygen, hyperoxia, and hypoxia. (See
         <a class="local">
          'Goals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our suggested approach to setting target ranges for SpO
         <sub>
          2
         </sub>
         is as follows (see
         <a class="local">
          'Oxygen target levels'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          During delivery room resuscitation
         </strong>
         – SpO
         <sub>
          2
         </sub>
         targets for neonates undergoing resuscitation in the delivery room are summarized in the table  (
         <a class="graphic graphic_table graphicRef138322" href="/z/d/graphic/138322.html" rel="external">
          table 1
         </a>
         ) and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">
          "Neonatal resuscitation in the delivery room", section on 'Pulse oximetry'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neonates &lt;28 weeks gestation
         </strong>
         – For most extremely preterm (EPT) neonates who require oxygen therapy, we recommend a SpO
         <sub>
          2
         </sub>
         target range of 90 to 95 percent during the first few weeks after birth rather than higher or lower levels (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). This target range minimizes both the low and high extreme oxygenation levels that have been associated with adverse outcomes, and it is supported by clinical trial data. If the infant still requires supplemental oxygen when the corrected postmenstrual age (PMA) is &gt;32 weeks, the SpO
         <sub>
          2
         </sub>
         target can be raised to &gt;95 percent. (See
         <a class="local">
          'Targets for neonates requiring ongoing respiratory support'
         </a>
         above and
         <a class="local">
          'Supporting evidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neonates 28 to &lt;34 weeks gestation
         </strong>
         – We also suggest a SpO
         <sub>
          2
         </sub>
         target range of 90 to 95 percent for preterm infants 28 to &lt;34 weeks GA (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Although data are lacking in more mature infants, indirect data from trials in EPT infants support this practice and this target range appears to be safe for preterm infants ≥28 weeks gestation. (See
         <a class="local">
          'Targets for neonates requiring ongoing respiratory support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neonates 34 to &lt;37 weeks gestation
         </strong>
         – For late preterm infants, we suggest a SpO
         <sub>
          2
         </sub>
         target range of 90 to 97 percent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A more liberal range is reasonable in these infants since they are at low risk of bronchopulmonary dysplasia and retinopathy of prematurity. (See
         <a class="local">
          'Targets for neonates requiring ongoing respiratory support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adherence
         </strong>
         – Maintaining infants within the targeted range is challenging. As a result, guidelines and institutional protocols for oxygen therapy in preterm neonates should aim for a safe SpO
         <sub>
          2
         </sub>
         range that can reliably be achieved in the real world practice setting. (See
         <a class="local">
          'Challenges adhering to oxygen targets'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3400694237">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges James Adams, Jr., MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dawson JA, Kamlin CO, Vento M, et al. Defining the reference range for oxygen saturation for infants after birth. Pediatrics 2010; 125:e1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quine D, Stenson BJ. Arterial oxygen tension (Pao2) values in infants &lt;29 weeks of gestation at currently targeted saturations. Arch Dis Child Fetal Neonatal Ed 2009; 94:F51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo A, Sola A, Baquero H, et al. Pulse oxygen saturation levels and arterial oxygen tension values in newborns receiving oxygen therapy in the neonatal intensive care unit: is 85% to 93% an acceptable range? Pediatrics 2008; 121:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bancalari E, Claure N. Oxygenation targets and outcomes in premature infants. JAMA 2013; 309:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polin RA, Bateman D. Oxygen-saturation targets in preterm infants. N Engl J Med 2013; 368:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RJ, Wang K, Köroğlu O, et al. Intermittent hypoxic episodes in preterm infants: do they matter? Neonatology 2011; 100:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sears JE, Pietz J, Sonnie C, et al. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology 2009; 116:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Whyte RK, Asztalos EV, et al. Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA 2013; 309:2111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BOOST II United Kingdom Collaborative Group, BOOST II Australia Collaborative Group, BOOST II New Zealand Collaborative Group, et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med 2013; 368:2094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askie LM, Darlow BA, Davis PG, et al. Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants. Cochrane Database Syst Rev 2017; 4:CD011190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manja V, Lakshminrusimha S, Cook DJ. Oxygen saturation target range for extremely preterm infants: a systematic review and meta-analysis. JAMA Pediatr 2015; 169:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manja V, Saugstad OD, Lakshminrusimha S. Oxygen Saturation Targets in Preterm Infants and Outcomes at 18-24 Months: A Systematic Review. Pediatrics 2017; 139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askie LM, Darlow BA, Finer N, et al. Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 2018; 319:2190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darlow BA, Marschner SL, Donoghoe M, et al. Randomized controlled trial of oxygen saturation targets in very preterm infants: two year outcomes. J Pediatr 2014; 165:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poets CF, Roberts RS, Schmidt B, et al. Association Between Intermittent Hypoxemia or Bradycardia and Late Death or Disability in Extremely Preterm Infants. JAMA 2015; 314:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh MC, Di Fiore JM, Martin RJ, et al. Association of Oxygen Target and Growth Status With Increased Mortality in Small for Gestational Age Infants: Further Analysis of the Surfactant, Positive Pressure and Pulse Oximetry Randomized Trial. JAMA Pediatr 2016; 170:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Fiore JM, Martin RJ, Li H, et al. Patterns of Oxygenation, Mortality, and Growth Status in the Surfactant Positive Pressure and Oxygen Trial Cohort. J Pediatr 2017; 186:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarrete CT, Wrage LA, Carlo WA, et al. Growth Outcomes of Preterm Infants Exposed to Different Oxygen Saturation Target Ranges from Birth. J Pediatr 2016; 176:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings JJ, Polin RA, Committee on Fetus and Newborn, American Academy of Pediatrics. Noninvasive Respiratory Support. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Zanten HA, Tan RN, van den Hoogen A, et al. Compliance in oxygen saturation targeting in preterm infants: a systematic review. Eur J Pediatr 2015; 174:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim K, Wheeler KI, Gale TJ, et al. Oxygen saturation targeting in preterm infants receiving continuous positive airway pressure. J Pediatr 2014; 164:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagadorn JI, Furey AM, Nghiem TH, et al. Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study. Pediatrics 2006; 118:1574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claure N, D'Ugard C, Bancalari E. Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: a pilot clinical trial. J Pediatr 2009; 155:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallenberger A, Poets CF, Horn W, et al. Closed-loop automatic oxygen control (CLAC) in preterm infants: a randomized controlled trial. Pediatrics 2014; 133:e379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waitz M, Schmid MB, Fuchs H, et al. Effects of automated adjustment of the inspired oxygen on fluctuations of arterial and regional cerebral tissue oxygenation in preterm infants with frequent desaturations. J Pediatr 2015; 166:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Zanten HA, Kuypers KLAM, Stenson BJ, et al. The effect of implementing an automated oxygen control on oxygen saturation in preterm infants. Arch Dis Child Fetal Neonatal Ed 2017; 102:F395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajdos M, Waitz M, Mendler MR, et al. Effects of a new device for automated closed loop control of inspired oxygen concentration on fluctuations of arterial and different regional organ tissue oxygen saturations in preterm infants. Arch Dis Child Fetal Neonatal Ed 2019; 104:F360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds PR, Miller TL, Volakis LI, et al. Randomised cross-over study of automated oxygen control for preterm infants receiving nasal high flow. Arch Dis Child Fetal Neonatal Ed 2019; 104:F366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dargaville PA, Franz A, Poets CF, Gale TJ. Automated oxygen control in the preterm infant: automation yes, but we need intelligence. Arch Dis Child Fetal Neonatal Ed 2019; 104:F346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen ML, Pellicer A, Hyttel-Sørensen S, et al. Cerebral Oximetry Monitoring in Extremely Preterm Infants. N Engl J Med 2023; 388:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichler G, Goeral K, Hammerl M, et al. Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth (COSGOD III): multicentre randomised phase 3 clinical trial. BMJ 2023; 380:e072313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyttel-Sorensen S, Greisen G, Als-Nielsen B, Gluud C. Cerebral near-infrared spectroscopy monitoring for prevention of brain injury in very preterm infants. Cochrane Database Syst Rev 2017; 9:CD011506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chock VY, Kwon SH, Ambalavanan N, et al. Cerebral Oxygenation and Autoregulation in Preterm Infants (Early NIRS Study). J Pediatr 2020; 227:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howarth C, Banerjee J, Leung T, et al. Cerebral Oxygenation in Preterm Infants With Necrotizing Enterocolitis. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhagen EA, Van Braeckel KN, van der Veere CN, et al. Cerebral oxygenation is associated with neurodevelopmental outcome of preterm children at age 2 to 3 years. Dev Med Child Neurol 2015; 57:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katheria AC, Stout J, Morales AL, et al. Association between early cerebral oxygenation and neurodevelopmental impairment or death in premature infants. J Perinatol 2021; 41:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tombolini S, De Angelis F, Correani A, et al. Is low cerebral near infrared spectroscopy oximetry associated with neurodevelopment of preterm infants without brain injury? J Perinat Med 2022; 50:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spaeder MC, Klugman D, Skurow-Todd K, et al. Perioperative Near-Infrared Spectroscopy Monitoring in Neonates With Congenital Heart Disease: Relationship of Cerebral Tissue Oxygenation Index Variability With Neurodevelopmental Outcome. Pediatr Crit Care Med 2017; 18:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch JC, Charpie JR, Ohye RG, Gurney JG. Near-infrared spectroscopy: what we know and what we need to know--a systematic review of the congenital heart disease literature. J Thorac Cardiovasc Surg 2009; 137:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rallis D, Karagianni P, Milona E, et al. Evaluation of Cerebral Oxygenation in Neonates with Sepsis with Near-Infrared Spectroscopy. Am J Perinatol 2017; 34:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norooz F, Urlesberger B, Giordano V, et al. Decompressing posthaemorrhagic ventricular dilatation significantly improves regional cerebral oxygen saturation in preterm infants. Acta Paediatr 2015; 104:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner M, Urlesberger B, Giordano V, et al. Outcome Prediction in Neonatal Hypoxic-Ischaemic Encephalopathy Using Neurophysiology and Neuroimaging. Neonatology 2022; 119:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeral K, Urlesberger B, Giordano V, et al. Prediction of Outcome in Neonates with Hypoxic-Ischemic Encephalopathy II: Role of Amplitude-Integrated Electroencephalography and Cerebral Oxygen Saturation Measured by Near-Infrared Spectroscopy. Neonatology 2017; 112:193.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 112392 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20439604" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Defining the reference range for oxygen saturation for infants after birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18285372" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Arterial oxygen tension (Pao2) values in infants&lt;29 weeks of gestation at currently targeted saturations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18450890" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pulse oxygen saturation levels and arterial oxygen tension values in newborns receiving oxygen therapy in the neonatal intensive care unit: is 85% to 93% an acceptable range?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23645072" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oxygenation targets and outcomes in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23642082" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Oxygen-saturation targets in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21986336" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intermittent hypoxic episodes in preterm infants: do they matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19157560" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10654946" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20472937" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Target ranges of oxygen saturation in extremely preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23644995" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23642047" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Oxygen saturation and outcomes in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28398697" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25664703" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Oxygen saturation target range for extremely preterm infants: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940510" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Oxygen Saturation Targets in Preterm Infants and Outcomes at 18-24 Months: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29872859" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24560181" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Randomized controlled trial of oxygen saturation targets in very preterm infants: two year outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26262797" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association Between Intermittent Hypoxemia or Bradycardia and Late Death or Disability in Extremely Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26746140" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of Oxygen Target and Growth Status With Increased Mortality in Small for Gestational Age Infants: Further Analysis of the Surfactant, Positive Pressure and Pulse Oximetry Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28279433" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Patterns of Oxygenation, Mortality, and Growth Status in the Surfactant Positive Pressure and Oxygen Trial Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27344218" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Growth Outcomes of Preterm Infants Exposed to Different Oxygen Saturation Target Ranges from Birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26715607" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Noninvasive Respiratory Support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26468116" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Compliance in oxygen saturation targeting in preterm infants: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24433828" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Oxygen saturation targeting in preterm infants receiving continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015549" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19595375" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: a pilot clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24470641" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Closed-loop automatic oxygen control (CLAC) in preterm infants: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25454938" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of automated adjustment of the inspired oxygen on fluctuations of arterial and regional cerebral tissue oxygenation in preterm infants with frequent desaturations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28209638" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The effect of implementing an automated oxygen control on oxygen saturation in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30154236" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of a new device for automated closed loop control of inspired oxygen concentration on fluctuations of arterial and different regional organ tissue oxygen saturations in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30464005" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Randomised cross-over study of automated oxygen control for preterm infants receiving nasal high flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30796060" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Automated oxygen control in the preterm infant: automation yes, but we need intelligence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37075142" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cerebral Oximetry Monitoring in Extremely Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36693654" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth (COSGOD III): multicentre randomised phase 3 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28869278" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cerebral near-infrared spectroscopy monitoring for prevention of brain injury in very preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32818482" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cerebral Oxygenation and Autoregulation in Preterm Infants (Early NIRS Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32848028" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cerebral Oxygenation in Preterm Infants With Necrotizing Enterocolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25382744" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cerebral oxygenation is associated with neurodevelopmental outcome of preterm children at age 2 to 3 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33589727" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association between early cerebral oxygenation and neurodevelopmental impairment or death in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35316597" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Is low cerebral near infrared spectroscopy oximetry associated with neurodevelopment of preterm infants without brain injury?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28067688" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Perioperative Near-Infrared Spectroscopy Monitoring in Neonates With Congenital Heart Disease: Relationship of Cerebral Tissue Oxygenation Index Variability With Neurodevelopmental Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19154918" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Near-infrared spectroscopy: what we know and what we need to know--a systematic review of the congenital heart disease literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27627794" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Evaluation of Cerebral Oxygenation in Neonates with Sepsis with Near-Infrared Spectroscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25619108" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Decompressing posthaemorrhagic ventricular dilatation significantly improves regional cerebral oxygen saturation in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35636405" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Outcome Prediction in Neonatal Hypoxic-Ischaemic Encephalopathy Using Neurophysiology and Neuroimaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28704822" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prediction of Outcome in Neonates with Hypoxic-Ischemic Encephalopathy II: Role of Amplitude-Integrated Electroencephalography and Cerebral Oxygen Saturation Measured by Near-Infrared Spectroscopy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
